Clinicopathologic profile of breast cancer patients treated with neoadjuvant chemotherapy at HUCFF/UFRJ
Keywords:
locally advanced breast cancer, neoadjuvant chemotherapy, pathological responseAbstract
Introduction: The objective of this study is to describe the profile of patients from a public institution, submitted to neoadjuvant chemotherapy (NACT), comparing the verified pathological response with literature data. Methods: Observational retrospective cohort study on breast cancer patients diagnosed between September 2001 and October 2018 and treated with NACT at Hospital Universitário Clementino Fraga Filho (HUCFF/UFRJ), located in Rio de Janeiro, Brazil. The adopted neoadjuvant chemotherapy regimen was based on anthracycline and docetaxel. Results: A total of 133 patients were evaluated. The average age in this group was 54 years (28-86), 49 women (37%) were under 50 years old. The following distribution by molecular subtype was observed: overexpression or amplification of the human epidermal growth factor receptor 2 (HER2+) (13 women, 26.6%), Luminal (19 women, 38.8%), and Triple-negative (TN) (17 women, 34.6%). The HER2+ and TN subtypes had a higher incidence of cases between 40-49 years and 50-59 years. As for the initial staging, 34% were IIIA; 26%, IIB; and 19%, IIIB. Only one patient did not undergo surgery after NACT, 33 (24.8%) underwent conservative surgery, and 99 patients (74.4%) underwent mastectomy. Regarding the axillary approach, 41 (31%) underwent sentinel lymph node biopsy and 88 (66%) had an indication for lymphadenectomy. In the anatomopathological evaluation of the surgery, 12 (9.1%) patients obtained a pathologic complete response (pCR) and 113 (84.9%), partial or no response to chemotherapy. Conclusion: This research enabled the identification of clinicopathologic characteristics and outcome of patients who received neoadjuvant chemotherapy in a public university service. The predominance of advanced tumors was observed, stressing the need for public health policies for the screening of breast cancer as well as the guarantee of timely treatment for diagnosed cases. The data somewhat reflect the difficulty that the public sector encounters to carry out the most appropriate treatment. The authors expect that this article, by analyzing the profile and the adopted treatment in real-life cases and in a public university institution, can contribute to the improvement of breast cancer treatment in Brazil.
Downloads
References
Instituto Nacional de Câncer José Alencar Gomes da Silva. Estimativa 2020: incidência de câncer no Brasil / Instituto Nacional de Câncer José Alencar Gomes da Silva [internet]. [cited on Oct. 13, 2020]. Available at: https://www.inca.gov.br/sites/ufu.sti.inca.local/files//media/document//estimativa-2020-incidencia-de-cancer-no-brasil.pdf.
Amin MB, Edge SB, Greene FL, Compton CC, Gershenwald JE, et al (Eds.). AJCC Cancer Staging Manual. 8th ed. Chicago: Springer;2018.
Fisher B, Bryant J, Wolmark N, Mamounas E, Brown A, et al. Effect of preoperative chemotherapy on the outcome of women with operable breast cancer. J Clin Oncol. 1998;16(8):2672-85. https://doi.org/10.1200/JCO.1998.16.8.2672
Hortobagyi GN, Ames FC, Buzdar AU, Kau SW, McNeese MD, et al. Management of stage III primary breast cancer with primary chemotherapy, surgery, and radiation therapy. Cancer. 1988;62(12):2507-16. https://doi.org/10.1002/1097-0142(19881215)62:12<2507::AID-CNCR2820621210>3.0.CO;2-D
Buzdar AU, Singletary SE, Theriault RL, Booser DJ, Valero V, et al. Prospective evaluation of paclitaxel versus combination chemotherapy with fluorouracil, doxorubicin, and cyclophosphamide as neoadjuvant therapy in patients with operable breast cancer. J Clin Oncol. 1999;17(11):3412-7. https://doi.org/10.1200/JCO.1999.17.11.3412
Fumoleau P, Tubiana-Hulin M, Romieu G, Namer M, Delva R, et al. A randomized phase II study of 4 or 6 cycles of adriamycin/ taxol®(paclitaxel)as neoadjuvant treatment of breast cancer. Abstracts of the 24th Annual San Antonio Breast Cancer Symposium. San Antonio, Texas, USA. December 10-13, 2001. Breast Cancer Res Treat. 2001;69(3):209-325. PMID: 11762328.
Miller KD, McCaskill-Stevens W, Sisk J, Loesch DM, Monaco F, et al. Combination versus sequential doxorubicin and docetaxel as primary chemotherapy for breast cancer: a randomized pilot trial of the Hoosier Oncology Group. J Clin Oncol. 1999;17(10):3033-7. https://doi.org/10.1200/JCO.1999.17.10.3033
von Minckwitz G, Raab G, Caputo A, Schütte M, Hilfrich J, et al. Doxorubicin with Cyclophosphamide followed by Docetaxel every 21 days Compared with Doxorubicin and Docetaxel every 14 days as preoperative treatment in operable breast cancer: The Geparduo Study of the German Breast Group. J Clin Oncol. 2005;23(12):2676-85. https://doi.org/10.1200/JCO.2005.05.078
Bear HD, Anderson S, Brown A, Smith R, Mamounas EP, et al. The effect on tumor response of adding sequential preoperative docetaxel to preoperative doxorubicin and cyclophosphamide: preliminary results from National Surgical Adjuvant Breast and Bowel Project Protocol B-27. J Clin Oncol. 2003;21(22):4165-74. https://doi.org/10.1200/JCO.2003.12.005
Petrelli F, Borgonovo K, Cabiddu M, Ghilardi M, Barni S. Neoadjuvant chemotherapy and concomitant trastuzumab in breast cancer: a pooled analysis of two randomized trials. Anticancer Drugs. 2011;22(2):128-35. https://doi.org/10.1097/cad.0b013e32834120aa
Baselga J, Bradbury I, Eidtmann H, Di Cosimo S, Aura C, et al. First results of the neoaltto trial (big 01-06 / egf 106903): a phase III, randomized, open label, neoadjuvant study of lapatinib, trastuzumab,andtheircombinationpluspaclitaxelinwomenwith her2-positive primary breast cancer. Cancer Res. 2010;70(24):S3-3. https://doi.org/10.1158/0008-5472.SABCS10-S3-3
Gianni L, Pienkowski T, Im YH, Tseng LM, Liu MC, et al. 5-year analysis of neoadjuvant pertuzumab and trastuzumab in patients with locally advanced, inflammatory, or early-stage HER2-positive breast cancer (NeoSphere): a multicentre, open- label, phase 2 randomised trial. Lancet Oncol. 2016;17(6):791- 800. https://doi.org/10.1016/S1470-2045(16)00163-7
Rastogi P, Anderson SJ, Bear HD, Geyer CE, Kahlenberg MS, et al. Preoperative chemotherapy: updates of national surgical adjuvant breast and bowel project protocols B-18 and B-27. J Clin Oncol. 2008;26(5):778-85. https://doi.org/10.1200/JCO.2007.15.0235.
von Minckwitz G, Untch M, Blohmer JU, Costa SD, Eidtmann H, et al. Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes. J Clin Oncol. 2012;30(15):1796- 804. https://doi.org/10.1200/JCO.2011.38.8595.
Roché H, Fumoleau P, Spielmann M, Canon JL, Delozier T, et al. Sequential adjuvant epirubicin-based and docetaxel chemotherapy for node-positive breast cancer patients: the FNCLCC PACS 01 Trial. J Clin Oncol. 2006;24(36):5664-71. https://doi.org/10.1200/JCO.2006.07.3916.
Instituto Nacional de Câncer José Alencar Gomes da Silva. Informação dos registros hospitalares de câncer como estratégia de transformação: perfil do Instituto Nacional de Câncer José Alencar Gomes da Silva em 25 anos/Instituto Nacional de Câncer José Alencar Gomes da Silva. [internet]. [cited on Oct. 13, 2020]. Available at: https://www.inca.gov.br/sites/ufu.sti.inca.local/files//media/document//informacao- dos-registros-hospitalares-de-cancer-como-estrategia-de- transformacao.pdf
Simon SD, Bines J, Werutsky G, Nunes JS, Pacheco FC, et al. Characteristics and prognosis of stage I-III breast cancer subtypes in Brazil: the AMAZONA retrospective cohort study. Breast. 2019;44:113-9. https://doi.org/10.1016/j.breast.2019.01.008
Instituto Nacional de Câncer José Alencar Gomes da Silva. Confira as recomendações do Ministério da Saúde para o rastreamento do câncer de mama: mamografia de rotina deve ser feita entre os 50 e os 69 anos, a cada dois anos. [internet]. [cited on Dec. 24, 2020]. Available at: https://www.inca.gov. br/noticias/confira-recomendacoes-do-ministerio-da-saude- para-o-rastreamento-do-cancer-de-mama
Andrade DAP, Zucca-Matthes G, VIEIRA RAC, Andrade CTAE, Costa AM, et al. Quimioterapia neoadjuvante e resposta patológica: coorte retrospectiva. Einstein. 2013;11(4):446-50. https://doi.org/10.1590/S1679-45082013000400007
CintraJRD,TeixeiraMTB,DinizRW,GonçalvesJuniorH,Florentino TM, etal. Perfil imuno-histoquímico evariáveisclinicopatológicas no câncer de mama. Rev Assoc Med Bras. 2012;58(2):178-87. https://doi.org/10.1590/S0104-42302012000200013
Pessoa EC, Rodrigues JR, Michelin O, De Luca HV, Kamiya CP, et al. Avaliação da resposta à quimioterapia primária em amostra de mulheres brasileiras com tumores de mama localmente avançados. Rev Bras Ginecol Obstet. 2007;29(1):18- 26. https://doi.org/10.1590/S0100-72032007000100004
Bines J, Small IA, Sarmento R, Kestelman F, Silva S, et al. Does the Sequence of Anthracycline and Taxane Matter? The NeoSAMBA Trial. Oncologist. 2020;25(9):758-64. https://doi.org/10.1634/theoncologist.2019-0805.
Cortazar P, Zhang L, Untch M, Mehta K, Costantino JP, et al. Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis. Lancet. 2014;384(9938):164-72. https://doi.org/10.1016/S0140- 6736(13)62422-8
Symmans WF, Peintinger F, Hatzis C, Rajan R, Kuerer H, et al. Measurement of residual breast cancer burden to predict survival after neoadjuvant chemotherapy. J Clin Oncol. 2007;25(28):4414-22. https://doi.org/10.1200/JCO.2007.10.6823.
Schneeweiss A, Chia S, Hickish T, Harvey V, Eniu A, et al. Pertuzumab plus trastuzumab in combination with standard neoadjuvant anthracycline-containing and anthracycline- free chemotherapy regimens in patients with HER2-positive early breast cancer: a randomized phase II cardiac safety study (TRYPHAENA). Ann Oncol. 2013;24(9):2278-84. https://doi.org/2278-84. 10.1093/annonc/mdt182
Slamon D, Eiermann W, Robert N, Pienkowski T., Martin M, et al. Adjuvant trastuzumab in HER2-positive breast cancer. N Engl J Med. 2011;365:1273-83. https://doi.org/10.1056/NEJMoa0910383
Cardoso F, Kyriakides S, Ohno S, Penault-Llorca F, Poortmans P, et al. Early breast cancer: esmo clinical practice guidelines. Ann Oncol. 2019;30(8):1194-1220. https://doi.org/10.1093/annonc/mdz173
Masuda N, Lee SJ, Ohtani S, Young-Hyuck I, Eun-Sook L, et al. Adjuvant capecitabine for breast cancer after preoperative chemotherapy. N Engl J Med. 2017;376(22):2147-59. https://doi.org/10.1056/NEJMoa1612645
von Minckwitz G, Huang CS, Mano MS, Loibl S, Mamounas EP, et al. Trastuzumab emtansine for residual invasive her2- positive breast cancer. N Engl J Med. 2019;380(7):617-28. https://doi.org/10.1056/NEJMoa1814017
Denduluri N, Somerfield MR, Chavez-MacGregor M, Comander AH, Dayao Z, et al. Selection of Optimal Adjuvant Chemotherapy and Targeted Therapy for Early Breast Cancer: ASCO Guideline Update. J Clin Oncol. 2020;38:1-11. https://doi.org/10.1200/JCO.20.02510
Amorim G, Tavares M, Sahade M, Reinert T. Mama: doença localizada -neoadjuvância. [internet]. [cited on Dec. 26, 2020]. Available at: https://www.sboc.org.br/images/diretrizes/lote-8/Diretrizes%20SBOC%202020%20-%20Mama%20neoadjuvante%20p%C3%B3s-sugest%C3%B5es.pdf
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2021 Luís Claudio Belo Amendola, Maria de Fatima Dias Gaui, Ana Helena Pereira Correia Carneiro, Nathalie Henriques Silva Canedo
This work is licensed under a Creative Commons Attribution 4.0 International License.
